Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Acta Oncol ; 56(8): 1043-1047, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28270018

RESUMO

INTRODUCTION: Spatially fractionated radiation therapy (SFRT or grid therapy) has proven to be effective in management of bulky tumors. The aim of this project is to study the therapeutic ratio (TR) of helical Tomotherapy (HT)-based grid therapy using linear-quadratic cell survival model. MATERIAL AND METHODS: HT-based grid (or HT-GRID) plan was generated using a patient-specific virtual grid pattern of high-dose cylindrical regions using MLCs. TR was defined as the ratio of normal tissue surviving fraction (SF) under HT-GRID irradiation to an open debulking field of an equivalent dose that result in the same tumor cell SF. TR was estimated from DVH data on ten HT-GRID patient plans with deep seated, bulky tumor. Dependence of the TR values on radiosensitivity of the tumor cells and prescription dose was analyzed. RESULTS: The mean ± standard deviation (SD) of TR was 4.0 ± 0.7 (range: 3.1-5.5) for the 10 patients with single fraction maximum dose of 20 Gy to GTV assuming a tumor cell SF at 2 Gy (SF2t) value of 0·5. In addition, the mean ± SD of TR values for SF2t values of 0.3 and 0.7 were found to be 1 ± 0.1 and 18.0 ± 5.1, respectively. Reducing the prescription dose to 15 and 10 Gy lowered the respective TR values to 2.0 ± 0.2 and 1.2 ± 0.04 for a SF2t value of 0.5. CONCLUSION: HT-GRID therapy demonstrates a significant therapeutic advantage over uniform dose from an open field irradiation for the same tumor cell kill. TR increases with the radioresistance of the tumor cells and with prescription dose.


Assuntos
Modelos Biológicos , Neoplasias/radioterapia , Tolerância a Radiação/efeitos da radiação , Planejamento da Radioterapia Assistida por Computador/métodos , Radioterapia de Intensidade Modulada , Humanos , Dosagem Radioterapêutica , Estudos Retrospectivos
2.
Chin Clin Oncol ; 5(3): 39, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-27164852

RESUMO

Partial breast irradiation (PBI) when added to lumpectomy demonstrates equivalent local recurrence and survival when compared to whole breast radiation. However, PBI can be delivered in much shorter time (5 days as compared to 6 weeks) and even intraoperatively as an one time dose. This article describes the many alternative techniques available for delivering PBI.


Assuntos
Neoplasias da Mama/radioterapia , Neoplasias da Mama/mortalidade , Neoplasias da Mama/cirurgia , Feminino , Humanos , Mastectomia Segmentar , Dosagem Radioterapêutica , Radioterapia Adjuvante/métodos , Ensaios Clínicos Controlados Aleatórios como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA